Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients

Breast cancer is the most common cancer and a major cause of morbidity and mortality in women worldwide annually. The proto-oncogene Human Epidermal growth factor Receptor-2(HER-2/neu) (C-erbB-2) has been localized to chromosome 17q and encodes a transmembrane tyrosine kinase growth factor recep...

Full description

Bibliographic Details
Main Authors:	Aung, Sanda, Mohd Noor, Noriah, Mohammad Amjad, Nasser, Abdullah, Nasuruddin, Phyu, Htike Myat
Format:	Conference or Workshop Item
Language:	English English English English
Published:	2014
Subjects:	R Medicine (General) RB Pathology RD Surgery
Online Access:	http://irep.iium.edu.my/39424/ http://irep.iium.edu.my/39424/3/IRIIE_2014-_Book_of_Abstracts.pdf http://irep.iium.edu.my/39424/5/IRIE_2014_B_001.jpg http://irep.iium.edu.my/39424/16/IRIE_2014.pdf http://irep.iium.edu.my/39424/19/IRIE_Abstract_2014.pdf

id	iium-39424
recordtype	eprints
spelling	iium-394242017-06-15T01:00:39Z http://irep.iium.edu.my/39424/ Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients Aung, Sanda Mohd Noor, Noriah Mohammad Amjad, Nasser Abdullah, Nasuruddin Phyu, Htike Myat R Medicine (General) RB Pathology RD Surgery Breast cancer is the most common cancer and a major cause of morbidity and mortality in women worldwide annually. The proto-oncogene Human Epidermal growth factor Receptor-2(HER-2/neu) (C-erbB-2) has been localized to chromosome 17q and encodes a transmembrane tyrosine kinase growth factor receptor. The activation of the Her-2/neu oncogene triggers a cascade of growth signals that results in gene activation, which contributes the uncontrolled growth and survival of cancer cells. Molecular biomarker of cerb-B2 (HER-2/neu) is the prognostic indicator to predict the outcome for women with breast cancer. The cross sectional descriptive study was carried out on 31 breast cancer patients admitted to Surgical Department, Hospital Tengku Ampuan Afzan, Kuantan for breast cancer operation, between January, 2012 and July, 2013. This study was approved by Medical research and Ethics Committee, Ministry of Health Malaysia and all the participants gave their written informed consent. The pre- and post-operative serum Her2/neu protein level in all types of breast cancer was measured by ELISA method. Histological grading was done according to Modified Bloom and Richardson Grading2. The data was analysed by using SPSS version 11.5. In 31 patients, the ages ranged from 38 to 77 years with a mean of 54 years. The mean serum concentrations of Her2/neu protein before and after operation were 1.88+1.527 ng/ml and 1.31+0.994) ng/ml, respectively. Paired Sample T test showed there is a significant correlation between pre- and post-operative serum level of Her2/neu (p=0.004). Mann Whitney U test analysis showed the pre-operative serum level of Her2/neu protein was associated with vascular invasion (p=0.009). However, there was no significant relation between prognostic biomarker Her2/neu and the clinical prognostic parameters of tumor size, lymph node involvement, lymphatic invasion, histological type and grade in all types of breast cancer. High HER-2/neu protein expression is associated with more ductal carcinoma in situ, invasive cancer, high cell proliferation rate, lack of response to hormone therapy, aggressive clinical behavior, development of metastasis, treatment resistance, cancer progression, decreased chance of survival and poor prognosis. However, Her2/neu overexpression tumours response to herceptin. Although the duration of study is short and the small size is small, serum Her2/neu protein level in breast cancer may predict the prognosis, response to therapy, and will be able to assist in breast cancer management. 2014-06-11 Conference or Workshop Item NonPeerReviewed application/pdf en http://irep.iium.edu.my/39424/3/IRIIE_2014-_Book_of_Abstracts.pdf application/pdf en http://irep.iium.edu.my/39424/5/IRIE_2014_B_001.jpg application/pdf en http://irep.iium.edu.my/39424/16/IRIE_2014.pdf application/pdf en http://irep.iium.edu.my/39424/19/IRIE_Abstract_2014.pdf Aung, Sanda and Mohd Noor, Noriah and Mohammad Amjad, Nasser and Abdullah, Nasuruddin and Phyu, Htike Myat (2014) Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients. In: International Research, Invention and Innovation Exhibition (IRIIE) 2014, 11th - 12th June 2014, International Islamic University Malaysia .
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English English English English
topic	R Medicine (General) RB Pathology RD Surgery
spellingShingle	R Medicine (General) RB Pathology RD Surgery Aung, Sanda Mohd Noor, Noriah Mohammad Amjad, Nasser Abdullah, Nasuruddin Phyu, Htike Myat Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
description	Breast cancer is the most common cancer and a major cause of morbidity and mortality in women worldwide annually. The proto-oncogene Human Epidermal growth factor Receptor-2(HER-2/neu) (C-erbB-2) has been localized to chromosome 17q and encodes a transmembrane tyrosine kinase growth factor receptor. The activation of the Her-2/neu oncogene triggers a cascade of growth signals that results in gene activation, which contributes the uncontrolled growth and survival of cancer cells. Molecular biomarker of cerb-B2 (HER-2/neu) is the prognostic indicator to predict the outcome for women with breast cancer. The cross sectional descriptive study was carried out on 31 breast cancer patients admitted to Surgical Department, Hospital Tengku Ampuan Afzan, Kuantan for breast cancer operation, between January, 2012 and July, 2013. This study was approved by Medical research and Ethics Committee, Ministry of Health Malaysia and all the participants gave their written informed consent. The pre- and post-operative serum Her2/neu protein level in all types of breast cancer was measured by ELISA method. Histological grading was done according to Modified Bloom and Richardson Grading2. The data was analysed by using SPSS version 11.5. In 31 patients, the ages ranged from 38 to 77 years with a mean of 54 years. The mean serum concentrations of Her2/neu protein before and after operation were 1.88+1.527 ng/ml and 1.31+0.994) ng/ml, respectively. Paired Sample T test showed there is a significant correlation between pre- and post-operative serum level of Her2/neu (p=0.004). Mann Whitney U test analysis showed the pre-operative serum level of Her2/neu protein was associated with vascular invasion (p=0.009). However, there was no significant relation between prognostic biomarker Her2/neu and the clinical prognostic parameters of tumor size, lymph node involvement, lymphatic invasion, histological type and grade in all types of breast cancer. High HER-2/neu protein expression is associated with more ductal carcinoma in situ, invasive cancer, high cell proliferation rate, lack of response to hormone therapy, aggressive clinical behavior, development of metastasis, treatment resistance, cancer progression, decreased chance of survival and poor prognosis. However, Her2/neu overexpression tumours response to herceptin. Although the duration of study is short and the small size is small, serum Her2/neu protein level in breast cancer may predict the prognosis, response to therapy, and will be able to assist in breast cancer management.
format	Conference or Workshop Item
author	Aung, Sanda Mohd Noor, Noriah Mohammad Amjad, Nasser Abdullah, Nasuruddin Phyu, Htike Myat
author_facet	Aung, Sanda Mohd Noor, Noriah Mohammad Amjad, Nasser Abdullah, Nasuruddin Phyu, Htike Myat
author_sort	Aung, Sanda
title	Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
title_short	Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
title_full	Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
title_fullStr	Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
title_full_unstemmed	Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
title_sort	comparison of tumour biomarker her-2/neu (c-erbb-2) before and after surgery in breast cancer patients
publishDate	2014
url	http://irep.iium.edu.my/39424/ http://irep.iium.edu.my/39424/3/IRIIE_2014-_Book_of_Abstracts.pdf http://irep.iium.edu.my/39424/5/IRIE_2014_B_001.jpg http://irep.iium.edu.my/39424/16/IRIE_2014.pdf http://irep.iium.edu.my/39424/19/IRIE_Abstract_2014.pdf
first_indexed	2023-09-18T20:56:39Z
last_indexed	2023-09-18T20:56:39Z
_version_	1777410348760956928

Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients

Similar Items